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Background/Aims: We aimed to investigate the incidence of 
second primary pancreatic cancer (PC) after colorectal can-
cer (CRC) and to identify risk factors associated with subse-
quent PC. Methods: The observed incidence of a subsequent 
PC in patients with CRC was standardized using a population 
with CRC from the Korean Central Cancer Registry (KCCR). 
The expected incidence rate of PC was obtained by assuming 
that the select group experienced the same cancer incidence 
as the corresponding general population in the KCCR. Re-
sults: The registry included 4,822 patients with CRC aged 45 
to 74 years, representing 16,725.1 person-years of follow-up. 
Thirteen patients (0.3%) were diagnosed with a subsequent 
PC, and the overall age-adjusted incidence of second primary 
PC was 269.6 per 100,000 cases. In contrast, the overall 
incidence of primary PC in the general population was 18.68 
per 100,000 individuals. The standardized incidence ratio 
of subsequent PC was 14.44, which was significantly higher 
in patients with CRC than in the general population. Sex, 
diabetes mellitus, smoking, body mass index, and a history 
of receiving chemotherapy as a treatment for CRC did not 
increase the risk of subsequent development of PC. Conclu-
sions: The risk of a second primary PC was higher in patients 
with CRC. Further studies are needed to identify the risk fac-
tors and generate a screening strategy for cancer survivors. 
(Gut Liver 2017;11:728-732)
Key Words: Pancreatic neoplasms; Colorectal neoplasms; 
Second primary neoplasm 
INTRODUCTION
Due to advances in diagnostic and therapeutic techniques, 
life expectancies for most cancers have increased over the past 
decades. However, despite medical progress, the prognosis of 
pancreatic cancer (PC) is still not favorable, and the 5-year 
survival rate has only shown a small increase.1 Merely 10% of 
PC patients are candidates for curative resection at the time of 
initial diagnosis, without any effective screening method avail-
able for early diagnosis of PC. Although intensive surveillance 
with endoscopic ultrasound for high-risk patients with familial 
PC could detect PC at an early stage, the cost-effectiveness of 
such screening method is questionable.2 To make matters worse, 
there are only a few chemotherapy options available for locally 
advanced, metastatic, or recurred PC. Despite recent positive 
results with combination chemotherapies, such as FOLFIRINOX3 
and nab-paclitaxel/gemcitabine,4 very few patients get these 
benefits due to poor Eastern Cooperative Oncology Group (ECOG) 
performance status and chemo-toxicities. In this regard, early 
diagnosis of PC and selection of high-risk patients are extremely 
important.
In general, it is assumed that a patient who previously had 
cancer (a cancer survivor) is at risk of developing new cancer in 
another organ.5 In particular, cancer survivors for certain gas-
trointestinal malignancies with long overall survival time such 
as gastric cancer or colorectal cancer (CRC) may be at a higher 
risk of a second primary cancer. Investigation of second pri-
mary PC can provide clues to etiologic factors, and also identify 
patients who need more intensive medical surveillance. In this 
study, we assessed the incidence of second primary PC in patients 
with CRC compared to the incidence of PC in the general popula-
tion, and investigated the risk factors for second primary PC.
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MATERIALS AND METHODS
1. Patients
From January 2001 to July 2009, we identified consecutive 
patients with diagnosis of CRC who were prospectively enrolled 
in the cancer registry database at Severance Hospital in Seoul, 
Korea. Clinical data were collected for the patients’ age, sex, 
comorbidities (diabetes mellitus [DM], body mass index [BMI] 
for obesity), and smoking history at the time of initial CRC di-
agnosis, as well as their chemotherapy history of CRC and the 
occurrence of second primary cancer during follow-up period. 
The diagnosis of malignancy in this registry was confirmed 
histologically. Follow-up data of these patients were collected 
until August 2011. We selected patients of ages between 45 and 
74 years. Follow-up duration was expressed as person-years of 
observation, and the risk of second primary PC was stratified 
by 10-year age groups and sex. The Institutional Review Board 
of Severance Hospital at Yonsei University approved this retro-
spective study.
2. Statistics
The observed incidence rate of second primary PC in CRC 
patients was standardized using a CRC population in the Korean 
Central Cancer Registry (KCCR) of the National Cancer Center.6 
The expected incidence rate of PC was obtained by assuming 
that these persons experienced the same cancer incidence as 
prevailed in the corresponding general population in the KCCR. 
The standardized incidence ratio (SIR) was calculated as the 
ratio of the observed number to the expected number of PC 
cases within the age and sex groups. Statistical significance was 
assessed under the assumption that the observed number of PC 
followed a Poisson distribution, as the occurrence of second pri-
mary PC was relatively rare.7 
A 95% confidence interval (CI) was calculated for each SIR 
using the Fisher exact test. To identify risk factors of PC, poten-
tial association of clinical factors with PC was evaluated using 
either the Pearson chi-square test or the Fisher exact test. To 
identify independent factors associated with development of 
a second primary PC, multivariate logistic regression analysis 
was performed. Adjusted odds ratios were calculated to measure 
the degree of association, while the Hosmer-Lemeshow test for 
goodness of fit was used to ensure that the calibration of multi-
variate analysis was significant for the development of PC. A p-
value less than 0.05 was considered significant, and statistical 
tests were two-sided. All statistical analyses were performed 
using SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
RESULTS
A total of 5,988 CRC patients were identified in the registry at 
our hospital, out of which 4,822 patients were eligible for this 
study. We excluded two patients who were diagnosed with PC, 
in concurrence with the initial diagnostic work up for CRC. The 
median age at initial diagnosis of CRC was 61.0 years (range, 
45.0 to 74.0 years), and 61.8% of patients were men. The me-
dian follow-up duration from CRC diagnosis was 40.1 months 
(range, 0 to 384.3 months). About one-fifth of CRC patients 
(19.1%) had a history of smoking, while three-fourths of them 
(73.5%) had received one or more chemotherapies. Patient char-
acteristics of this study are summarized in Table 1. 
Over a period of 16,725.09 person-years of observation, 13 
cases of PC (0.3%) developed in 4,822 CRC patients. The median 
age reported at initial CRC diagnosis was higher in patients with 
subsequent PC than those without PC (p=0.128). The median 
time interval between diagnosis of CRC and development of PC 
was 45.57 months (range, 9.46 to 119.50 months). There were 
one stage I PC, six stage II, one stage III, and five stage IV. The 
distribution of subsequent PC, by sex and age at initial CRC di-
agnosis is displayed in Table 2.
Table 3 shows the SIR of second primary PC following CRC, 
according to sex and age groups. Overall SIR was significantly 
higher in CRC patients compared to the general population (SIR, 
14.44; 95% CI, 12.71 to 16.16). An increased risk of subsequent 
PC was noted for both sexes: SIR 10.07 (95% CI, 8.78 to 11.36) 
in men and 22.87 (95% CI, 20.39 to 25.35) in women. However, 
the SIR of PC after CRC did not tend to increase linearly with 
aging.
To explore the risk factors in more detail, we performed ad-
ditional analysis by stratifying by the following factors: age at 
Table 1. Demographic Characteristics of Patients with Colorectal Cancer 
Variable Value
Total patients 4,822
Male:female 2,981 (61.8):1,841 (38.2)
Age at initial diagnosis, yr  61.0 (45.0–74.0)
Age group, yr*
    45–54 1,153 (23.9)
    55–64 1,962 (40.7)
    65–74 1,707 (35.4)
Follow-up duration, mo  40.1 (0–384.3)
Total follow-up duration, person-year 16,725.09
Body mass index ≥25 kg/m2 1,289 (26.7)
Diabetes mellitus  670 (13.9)
Smoking history 
    Smoker or ex-smoker  922 (19.1)
    Never smoker  3,813 (79.1)
    Unknown  87 (1.8)
Chemotherapy for colorectal cancer  3,543 (73.5)
Data are presented as number (%) or median (range).
*The age at the diagnosis of colorectal cancer was divided into 10-
year groups.
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initial diagnosis of CRC, sex, DM, smoking, BMI, and history of 
chemotherapy for CRC (Table 4). We found no significant factor 
for increasing the risk of subsequent PC. 
DISCUSSION
With the general adoption of screening colonoscopy and 
the progress in chemotherapy and surgical techniques, the 
5-year survival rate of CRC has increased to 65%.8 As a result, 
Table 2. Clinical Features of Patients with Colorectal Cancer Who Did or Did Not Subsequently Develop Pancreatic Cancer
Variable CRC patients with subsequent PC CRC patients without PC p-value
No. of patients 13 4,809
Male sex 7 (53.8) 2,974 (61.8) 0.576
Age, yr  65.0 (48.0–72.0)  61.0 (45.0–74.0) 0.128
Age group, yr*
    45–54 1 (7.7) 1,152 (24.0)
    55–64  4 (30.8) 1,958 (40.7)
    65–74  8 (61.5) 1,699 (35.3)
BMI ≥25 kg/m2  3 (23.1) 1,286/4,649 (27.7)† >0.999
Diabetes mellitus  4 (30.8) 666/4,754 (14.0)‡ 0.098
Smoking history 0.296
    Smoker or ex-smoker  4 (30.8)  918/4,722 (19.4)
    Never smoker  9 (69.2) 3,804/4,722 (80.6)§
Chemotherapy for CRC 10 (76.9) 3,533/4,598 (76.8)ΙΙ >0.999
Time to diagnosis of PC, mo  45.57 (9.46–119.50) -
Data are presented as number (%) or median (range).
CRC, colorectal cancer; PC, pancreatic cancer; BMI, body mass index.
*The age at the diagnosis of colorectal cancer was divided into 10-year groups; †We excluded 160 patients whose BMI was not identified in this 
analysis; ‡We excluded 55 patients  whose DM history was not identified in this analysis; §We excluded 87 patients who did not answer the smok-
ing history in this analysis; ΙΙWe excluded 211 patients whose chemotherapy history was not identified in this analysis.
Table 3. SIR of Second Primary Pancreatic Cancer after Colorectal Cancer, Stratified by Age 
Age at initial diagnosis Observed no.* Expected no.† SIR 95% CI
Male sex, yr
    45–54 152.21 8.70 17.50 14.72–20.27
    55–64 163.00 26.54 6.14 5.20–7.08
    65–74 364.63 58.49 6.23 5.59–6.87
    Total 234.82 23.32 10.07  8.78–11.36
Female sex, yr
    45–54 0 4.18 0 -
    55–64 272.11 13.44 20.25 17.84–22.65
    65–74 655.74 36.4 18.01 16.64–19.39
    Total 325.91 14.25 22.87 20.39–25.35
All patients, yr
    45–54 86.73 6.47 13.40 10.58–16.23
    55–64 203.87 19.87 10.26  8.85–11.67
    65–74 468.66 46.12 10.16 9.24–11.08
    Total 269.60 18.68 14.44 12.71–16.16
SIR, standardized incidence ratio; CI, confidence interval.
*The observed incidence of second primary pancreatic cancer (PC) in patients with colorectal cancer (CRC) was standardized using a population 
with CRC from the Korean Central Cancer Registry (KCCR) of the National Cancer Center; †The expected incidence rate of PC was obtained from 
the KCCR.
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CRC survivors have a higher chance of developing a second 
primary malignancy, especially cancers that have similar car-
cinogenic mechanisms as those of CRC. Additionally, there has 
been an increase in the number of reported incidences of other 
solid organ malignancies after CRC, such as prostate cancer in 
men; breast, uterus, and ovarian cancers in women; and small 
intestine cancers in both sexes.9 In this regard, we supposed 
that PC would likely develop in patients with CRC due to the 
overlapping genetic predisposition. However, since patients 
with PC represent only a minority of the total cancer popula-
tion, there are discrepant reports of the risk of second primary 
PC after CRC, depending on the type of research. Data from the 
Surveillance, Epidemiology, and End Results registries showed 
that CRC survivors had a higher risk of subsequent pancreatic 
adenocarcinoma (SIR, 1.22; 95% CI, 1.09 to 1.35).10 A nation-
wide epidemiologic study from Sweden reported that the risk of 
second primary PC in colon cancer patients increased, by 1.77-
fold in men (95% CI, 1.42 to 2.19) and 1.34-fold in women (95% 
CI, 1.02 to 1.72).11 However, the risk was not significant for 
rectal cancer (SIR, 0.94; 95% CI, 0.64 to 1.32 in men; SIR, 1.09; 
95% CI, 0.70 to 1.62 in women) in the same study. On the other 
hand, a 50-year observational study conducted in Connecticut, 
United States showed that patients with rectal cancer had a re-
duced risk of PC.12 In an international multicenter study, Shen 
et al.13 reported that the risk of PC following CRC was as low as 
0.9-fold (SIR, 0.88; 95% CI, 0.82 to 0.94).
Results from our current study showed that patients with CRC 
had a very high risk of developing PC compared to the general 
population. The overall incidence of PC in CRC patients aged 
45 to 74 years was 269.60 per 100,000 patients, which was 
significantly higher than the 18.68 per 100,000 people reported 
in the general population of the same age (SIR, 14.44; 95% CI, 
12.71 to 16.16). The incidence of PC in our study might be high 
compared to other studies, since we monitored our patients very 
closely and thoroughly conducted diagnosis of PC. In addi-
tion, our results reflect the current trend of growing incidences 
of PC in the Korean population.14 It is also possible that PC 
and CRC share a more common etiology in Korea compared to 
other countries. Although we tried to rule out the possibility of 
metastasis and recurrence of CRC at the pancreas by imaging 
and pathologic evaluation, metastases might not have been dif-
ferentiated from primary PC in some cases. Further studies are 
needed to validate and explain the high risk of subsequent PC 
in Korea.
In spite of high incidence of subsequent PC in CRC patients, 
PC tended to be diagnosed at the early stage. There is no sta-
tistics of PC stage at diagnosis in Korean general population, 
but in the United States, about 37% of PC was either resectable 
or locally advanced.15 In this study about 62% of patients had 
resectable or locally advanced PC. Awareness of cancer risk and 
regular follow up could play a role in this trend. Also, there also 
could be difference in cancer behavior between first and second 
PC. This result suggests that well planned surveillance would be 
beneficial for early detection and treatment of subsequent PC 
in CRC survivors, which would ultimately bring survival gain. 
More studies are needed to understand the characteristics of 
subsequent PC.
Risk factors for subsequent PC were analyzed by DM, sex, 
aging, smoking, obesity, and chemotherapy history for CRC. 
However, we could not identify any significant risk factor for 
increasing subsequent PC. DM has previously been suggested to 
be a risk factor for PC in other studies.16,17 In our study, CRC pa-
tients with DM showed higher adjusted odds ratio (AOR) of 2.647 
for subsequent PC, but there was no statistical significance (95% 
CI, 0.799 to 8.777). As in most adult tumors, the incidence of 
PC is age-dependent,18 but increased age showed only a slight 
increased risk without statistical significance (AOR, 1.058; 95% 
CI, 0.979 to 1.144). The SIR tended to be higher in women (SIR, 
22.87) than in men (SIR, 10.07), but the sexual difference was 
not significant (p=0.211). Although other factors such as smok-
ing, alcohol drinking, BMI, and previous chemotherapy have 
been suggested as risk factors for other types of cancer, these 
variables were not significant in our study. In previous studies, 
an increased risk of PC was observed in patients with familial 
adenomatous polyposis syndrome/Gardner’s syndrome com-
pared to the general population.19 Since cancer syndromes and 
familial PC are very rarely reported in Korea, there was a mini-
mal relationship between familial PC or cancer syndromes and 
patients with subsequent PC in our registry.
This study has several limitations regarding generalization of 
the results. First, although the data were obtained prospectively, 
our analyses were performed retrospectively. Such investiga-
tional design may have presented some inherent drawbacks 
that could affect the results. For example, genetic abnormalities 
related to CRC and PC could not be identified. This informa-
tion would have been very useful for determining the effects of 
genetic factors. Second, since our study was based on a single 
cancer registry, only a few PCs accumulated and the data was 
limited for providing reliable and robust results. Third, our in-
clusion of only histologically confirmed cases of PC in the anal-
Table 4. Relative Risks of Subsequently Developing Pancreatic Cancer 
According to Age, Sex, Smoking, DM, BMI, and Prior Chemotherapy
Adjusted OR 95% CI p-value
DM 2.647 0.799–8.777 0.111
Age at diagnosis of CRC 1.058 0.979–1.144 0.156
Smoking 2.724  0.687–10.801 0.154
BMI ≥25 kg/m2 0.729 0.199–2.671 0.634
Chemotherapy for CRC 1.063 0.290–3.902 0.926
Female sex 2.265 0.630–8.146 0.211
DM, diabetes mellitus; BMI, body mass index; OR, odds ratio; CI, 
confidence interval; CRC, colorectal cancer. 
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ysis may have caused underestimation of the disease. The loss 
of CRC patients to follow-up is also a point to be considered. 
For more reliable results, either a nationwide or an international 
multicenter study from high-quality cancer registries should be 
organized, and these databases should be combined to investi-
gate relative risks and factors associated with PC.
In conclusion, we found that CRC survivors are relatively at a 
higher risk for second primary PC compared to the general pop-
ulation in Korea. In order to determine how often the patients 
should be screened and the optimal modality for screening, we 
recommend a nationwide CRC cohort study to be initiated and 
followed for the lifetime of patients, in which researchers collect 
and analyze detailed data including the patients’ genetic abnor-
malities, family history, and medical history.
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